Quick Answer
C4 Therapeutics, Inc. reported Total Revenue of $35.95 million for fiscal year 2025.
C4 Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $35.95M | +1.0% |
| 2024 | $35.58M | +71.4% |
| 2023 | $20.76M | -33.3% |
| 2022 | $31.10M | -32.1% |
| 2021 | $45.78M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.23M | -26.9% | +73.8% |
| June 30, 2025 | $6.46M | -46.2% | -10.7% |
| March 31, 2025 | $7.24M | +138.2% | -52.9% |
| September 30, 2024 | $15.36M | +38.7% | +28.0% |
| June 30, 2024 | $12.01M | +350.7% | +295.1% |
| March 31, 2024 | $3.04M | -19.2% | -72.6% |
| September 30, 2023 | $11.07M | +63.9% | +315.6% |
| June 30, 2023 | $2.66M | -80.7% | -29.1% |
- C4 Therapeutics, Inc. showed an increase of +1.0% in Total Revenue compared to the prior fiscal year.
- Over the 2021–2025 period, C4 Therapeutics, Inc.’s total revenue has declined by 21.5% (from $45.78 million to $35.95 million).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: